We are now in GN territory this month - or rather ANCA Vasculitis month! First we start off with this paper from London, which uses some data from the RAVE trial along with additional experiments to show some intriguing results on the role of MPO.
Background
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Background
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
Background
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
Background
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
